FindTrial
Sign In

To explore the application and safety of PEG-rhG-CSF in the prevention of granulocytopenia after TPF chemotherapy for head and neck tumors

To explore the application and safety of PEG-rhG-CSF in the prevention of granulocytopenia after TPF chemotherapy for head and neck tumors

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100043370
Enrollment
Unknown
Registered
2021-02-11
Start date
2019-10-01
Completion date
Unknown
Last updated
2021-06-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Head and Neck tumor

Interventions

case series:Nil

Sponsors

Cancer Hospital of Guizhou Province
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1.Patients receiving TPF chemotherapy for head and neck tumors. 2.The patients were treated with pegylated recombinant human granulocyte stimulating factor (PEG-rhG-CSF).

Exclusion criteria

Exclusion criteria: Refused pegylated recombinant human granulocyte stimulating factor (PEG-rhG-CSF) treatment.

Design outcomes

Primary

MeasureTime frame
Adverse Events;—

Countries

China

Contacts

Public ContactJin Feng

Department of Head and Neck Oncology, Cancer Hospital of Guizhou Province

jinf8865@yeah.net+86 13985124806

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026